Overcoming the challenges of implementing high value tests in the clinical lab

JMSACL Logo
Educational Grants supported in part by:
& Brian Kelly

Invited Speakers

Tue April 05 @ 15:00 (03:00 PM) in De Anza
Beyond the Human Genome: A Million Person Precision Population Health Project
Leroy Hood
Institute for Systems Biology

The vision of this project is that we will develop the infrastructure to employ a data-driven approach to optimizing the health trajectory of individuals for body and brain. We have two large populations (5000 and 10,000) that have validated this approach for body and brain health, respectively. These studies have led to us pioneering the science of wellness and prevention. This project will require the acquisition of key partners for execution, which will be delineated. We are approaching the Federal Government for funding, as we did for the first Human Genome Project. This project will lead to striking new knowledge about medicine, it will catalyze the initiation of start-up companies and it will catalyze a paradigm shift in healthcare from a disease orientation to a wellness and prevention orientation. This will catalyze the largest paradigm shift in medicine, ever.
Tue April 05 @ 16:00 (04:00 PM) in De Anza
The Clinical Laboratory Perspective on Wellness Testing: Let’s Take a Look Under the Hood
Geoff Baird
University of Washington

As medical science continues to make gains in the elucidation of disease pathophysiology and the discovery of cures , some have questioned the value of dedicating dwindling financial resources to maintaining wellness rather than to fighting disease per se. While both approaches are meritorious and complementary, neither approach is alone sufficient to ensure the health of a population. One major problem with the focus on wellness is the Bayesian dilemma that the positive predictive value of clinical laboratory testing in apparently healthy people is often low, as the specificities of few clinical tests are high enough to ensure that most positive results are true. The impact of this dilemma on laboratory-based wellness approaches will be discussed.
Tue April 05 @ 16:00 (04:00 PM) in De Anza

Mari DeMarco
University of British Columbia

Wed April 06 @ 08:00 (08:00 AM) in De Anza
Glycoproteins as Biomarkers for Cancers
Carlito Lebrilla
UC Davis

Wed April 06 @ 09:00 (09:00 AM) in De Anza

Stefani Thomas
University of Minnesota

Thu April 07 @ 14:00 (02:00 PM) in De Anza

Barbara Engelhardt
Princeton University

Fri April 08 @ 09:00 (09:00 AM) in De Anza
Addressing Hurdles in Clinical Translation of Targeted Proteomics
Jeffrey Whiteaker
Fred Hutchinson Cancer Research Center
Quantifying proteins and post-translational modifications will improve precision medicine, but several hurdles remain to adopting proteomics to the clinical laboratory. Dr. Whiteaker will discuss successes and remaining challenges for incorporating targeted proteomic measurements in clinical trials and other clinical applications.